Genmab to acquire ADC developer ProfoundBio for $1.8B cash

Danish antibody specialist Genmab is paying $1.8 billion in cash to scoop up ProfoundBio and throw its hat into the packed antibody-drug conjugate ring.

ProfoundBio brings to the table three clinical candidates generated on its technology platform, including a Phase 2 ADC being tested to treat ovarian cancer and other…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks